奥希替尼与血管内皮生长因子受体抑制剂联合用于EGFR突变型非小细胞肺癌：旧方案还是新方案？ - Suppr | 超能文献

Combination of Osimertinib and Vascular Endothelial Growth Factor Receptor Inhibitors for -Mutated Non-Small Cell Lung Cancer: Old or New Regimen?

作者信息

Kenmotsu Hirotsugu

机构信息

Division of Thoracic Oncology, Shizuoka Cancer Center, Nagaizumi-cho, Sunto-gun, Japan.

出版信息

J Clin Oncol. 2025 Feb;43(4):369-372. doi: 10.1200/JCO-24-01921. Epub 2024 Oct 11.

DOI:10.1200/JCO-24-01921

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Combination of Osimertinib and Vascular Endothelial Growth Factor Receptor Inhibitors for -Mutated Non-Small Cell Lung Cancer: Old or New Regimen?奥希替尼与血管内皮生长因子受体抑制剂联合用于EGFR突变型非小细胞肺癌：旧方案还是新方案？

J Clin Oncol. 2025 Feb;43(4):369-372. doi: 10.1200/JCO-24-01921. Epub 2024 Oct 11.

2

Impact of First-Line Osimertinib and Other EGFR-Tyrosine Kinase Inhibitors on Overall Survival in Untreated Advanced EGFR-Mutated Non-small Cell Lung Cancer in Japan: Updated Data from TREAD Project 01.日本未经治疗的晚期 EGFR 突变型非小细胞肺癌一线奥希替尼和其他 EGFR 酪氨酸激酶抑制剂对总生存期的影响：来自 TREAD 项目 01 的更新数据。

Target Oncol. 2024 Nov;19(6):925-939. doi: 10.1007/s11523-024-01094-5. Epub 2024 Sep 20.

3

Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC.第三代 EGFR 抑制剂奥希替尼联合培美曲塞或顺铂在 EGFR 突变的 NSCLC 临床前模型中发挥持久的抗肿瘤作用。

J Exp Clin Cancer Res. 2019 May 28;38(1):222. doi: 10.1186/s13046-019-1240-x.

4

Fingerprint loss during combination therapy using osimertinib and anlotinib: A case report.使用奥希替尼和安罗替尼联合治疗期间指纹缺失：一例报告。

J Clin Pharm Ther. 2022 Feb;47(2):248-250. doi: 10.1111/jcpt.13480. Epub 2021 Jul 8.

5

ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in -Mutated Non-Small Cell Lung Cancer.ONO-7475，一种新型的 AXL 抑制剂，抑制了 - 突变非小细胞肺癌对初始 EGFR-TKI 治疗的适应性耐药。

Clin Cancer Res. 2020 May 1;26(9):2244-2256. doi: 10.1158/1078-0432.CCR-19-2321. Epub 2020 Jan 17.

6

Notch pathway regulates osimertinib drug-tolerant persistence in EGFR-mutated non-small-cell lung cancer.Notch 通路调控 EGFR 突变型非小细胞肺癌中奥希替尼耐药性的持续存在。

Cancer Sci. 2023 Apr;114(4):1635-1650. doi: 10.1111/cas.15674. Epub 2022 Dec 7.

7

Recurrence as a small cell lung cancer transformation in a resected stage IIIA EGFR-mutated non-small cell lung cancer treated with adjuvant osimertinib: a case report.接受辅助奥希替尼治疗的 IIIA 期表皮生长因子受体（EGFR）突变非小细胞肺癌切除术后复发为小细胞肺癌转化：一例报告

Transl Lung Cancer Res. 2025 Jan 24;14(1):287-291. doi: 10.21037/tlcr-24-830. Epub 2025 Jan 16.

8

A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer.ADAURA 研究结果的简明报告：奥希替尼用于早期 EGFR 突变型非小细胞肺癌术后患者。

Future Oncol. 2021 Dec 1;17(35):4827-4835. doi: 10.2217/fon-2021-0752. Epub 2021 Nov 1.

9

Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial.奥希替尼联合贝伐珠单抗对比奥希替尼用于既往接受表皮生长因子受体酪氨酸激酶抑制剂治疗的 EGFR T790M 突变型非小细胞肺癌患者的疗效：西日本肿瘤学组 8715L 期随机临床试验。

JAMA Oncol. 2021 Mar 1;7(3):386-394. doi: 10.1001/jamaoncol.2020.6758.

10

Afatinib plus bevacizumab combination after osimertinib resistance in advanced EGFR-mutant non-small cell lung cancer: Phase II ABCD-study.奥希替尼耐药后阿法替尼联合贝伐珠单抗治疗晚期 EGFR 突变型非小细胞肺癌：Ⅱ期 ABCD 研究。

Lung Cancer. 2024 Nov;197:107988. doi: 10.1016/j.lungcan.2024.107988. Epub 2024 Oct 5.

引用本文的文献

1

Final Survival Outcomes With Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated -Mutated Metastatic NSCLC: RELAY Japanese Subset.雷莫西尤单抗联合厄洛替尼与安慰剂联合厄洛替尼用于未经治疗的EGFR突变型转移性非小细胞肺癌患者的最终生存结果：RELAY研究日本亚组

JTO Clin Res Rep. 2025 Feb 28;6(6):100819. doi: 10.1016/j.jtocrr.2025.100819. eCollection 2025 Jun.